FDA and Industry Collaborate to Predict Liver Toxicity in Human Drug Trials
News Nov 09, 2005
The Liver Toxicology Biomarker Study (LTBS) , to be conducted under a Cooperative R&D Agreement (CRADA) between the FDA's National Center for Toxicological Research (NCTR) and the pharmaceutical industry, aims to discover signs of human liver toxicity in a standard test used in the initial stages of drug development.
"Liver toxicity is a common reason for drug development failure," said Dr. Janet Woodcock, FDA's Deputy Commissioner for Operations and the principal author of the FDA's March 2004 report, Innovation/Stagnation: Challenge & Opportunity on the Critical Path to New Medical Products.
"In part, this is due to the fact that the safety evaluation relies on decades-old technologies that may recognize safety problems only after extensive clinical studies," Dr. Woodcock noted.
"By identifying biomarkers for liver toxicity at the start of the development process, this research should yield important benefits for industry, FDA and the public" The CRADA procedure routinely governs FDA's collaborative studies with the private sector.
The LTBS has been designed by FDA and BG Medicine with input from other pharmaceutical companies, and will be conducted, with their collaboration, at the NCTR lab in Jefferson AR and BG Medicine in Waltham MA.
Participating companies will receive access to all project data and a perpetual license to any discovered biomarkers.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018